Inactive Instrument
Allied Corp. Stock Other OTC
Stocks
ALID
US0191141078
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.3M 1.14M 1.05M 976K 1.85M 124M 1.88M 12.57M 4.89M 61.01M 4.89M 4.79M 210M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.6M 6.07M 5.65M 10.73M 719M 10.89M 72.83M 28.31M 353M 28.34M 27.74M 1.22B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
52.84% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -5.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 2020-05-01 |
| Director | Title | Age | Since |
|---|---|---|---|
James Smeeding
BRD | Director/Board Member | - | 2020-05-01 |
| Director/Board Member | - | - | |
Abdul Nnyenje
BRD | Director/Board Member | - | 2024-10-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.00% | -5.00% | - | - | 117 | ||
| +0.69% | +3.46% | +332.15% | +16.27% | 2.71B | ||
| +2.52% | +14.79% | +154.69% | +149.49% | 1.88B | ||
| 0.00% | -0.57% | -22.33% | +111.82% | 455M | ||
| +18.37% | +20.83% | +28.89% | +45.00% | 62.42M | ||
| Average | +3.32% | +10.45% | +123.35% | +80.64% | 1.28B | |
| Weighted average by Cap. | +1.52% | +9.23% | +231.54% | +74.19% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.86 0.1 0.7 0.27 3.37 0.27 0.26 11.63 | 0.1 0.08 0.08 0.07 0.14 9.16 0.14 0.93 0.36 4.5 0.36 0.35 15.51 |
| Net income | -10.68M -9.33M -8.58M -7.99M -15.16M -1.02B -15.39M -103M -40.03M -500M -40.07M -39.21M -1.72B | -3.98M -3.48M -3.19M -2.98M -5.65M -379M -5.73M -38.35M -14.91M -186M -14.93M -14.6M -641M |
| Net Debt | 5.65M 4.94M 4.54M 4.23M 8.03M 538M 8.15M 54.51M 21.19M 265M 21.21M 20.76M 912M | 6.25M 5.46M 5.02M 4.68M 8.87M 595M 9.01M 60.26M 23.42M 292M 23.45M 22.95M 1.01B |
Employees
-
Sector
Pharmaceuticals
















